Effect of albumin on artificial membrane permeation of acidic drugs
Original scientific paper
DOI:
https://doi.org/10.5599/admet.3700Keywords:
Free fraction theory, bovine serum albumin, phospholipids, lipophilicityAbstract
Background and purpose: The free fraction theory (FFT) plays a central role in pharmacokinetics and pharmacodynamics. However, for acidic drugs, deviations from FFT have been reported in cell‑based assays involving albumin binding. The purpose of the present study was to investigate the effect of albumin on the passive membrane permeation of acidic drugs in the parallel artificial membrane permeation assay (PAMPA). Experimental approach: Eight acidic drugs (atorvastatin, bosentan, entacapone, fluvastatin, meloxicam, pitavastatin, rosuvastatin, and tolbutamide) were used as model drugs. The PAMPA membrane consisted of phospholipids dissolved in decane. The effective permeation coefficient (Pe) was measured in the absence and presence of 4 % bovine serum albumin (BSA) in the donor solution. The unbound fraction (fu) was determined using equilibrium dialysis. Concentration dependence and phospholipid‑composition dependence of Pe were examined. Key results: Pe was substantially reduced by the addition of BSA, showing good consistency with FFT. The minor deviation from FFT was explained by a concentration‑dependent increase in the membrane permeability of unbound drug molecules, except for rosuvastatin. The effect of BSA on the permeability of rosuvastatin was influenced by phospholipid composition, possibly suggesting albumin-phospholipid interactions. Conclusion: PAMPA permeation showed good consistency with FFT. The slight deviations from FFT observed for the low‑permeability drugs can be explained by the concentration dependence of unbound drug permeability, except for rosuvastatin.
Downloads
References
[1] S.G. Summerfield, J.W.T. Yates, D.A. Fairman. Free Drug Theory - No Longer Just a Hypothesis? Pharmaceutical Research 39 (2022) 213-222. https://doi.org/10.1007/s11095-022-03172-7 DOI: https://doi.org/10.1007/s11095-022-03172-7
[2] I. Loryan, A. Reichel, B. Feng, C. Bundgaard, C. Shaffer, C. Kalvass, D. Bednarczyk, D. Morrison, D. Lesuisse, E. Hoppe, G.C. Terstappen, H. Fischer, L. Di, N. Colclough, S. Summerfield, S.T. Buckley, T.S. Maurer, M. Fridén. Unbound Brain-to-Plasma Partition Coefficient, Kp,uu,brain - a Game Changing Parameter for CNS Drug Discovery and Development. Pharmaceutical Research 39 (2022) 1321-1341. https://doi.org/10.1007/s11095-022-03246-6 DOI: https://doi.org/10.1007/s11095-022-03246-6
[3] P.J.H. Webborn, K. Beaumont, I.J. Martin, D.A. Smith. Free Drug Concepts: A Lingering Problem in Drug Discovery. Journal of Medicinal Chemistry 68 (2025) 6850-6856. https://doi.org/10.1021/acs.jmedchem.5c00725 DOI: https://doi.org/10.1021/acs.jmedchem.5c00725
[4] J.A. Schulz, D.M. Stresser, J.C. Kalvass. Plasma protein-mediated uptake and contradictions to the free drug hypothesis: a critical review. Drug Metabolism Reviews 55 (2023) 205-238. https://doi.org/10.1080/03602532.2023.2195133 DOI: https://doi.org/10.1080/03602532.2023.2195133
[5] T. Baba, A. Touchi, K. Ito, Y. Yamaguchi, Y. Yamazoe, Y. Ohno, Y. Sugiyama. Effects of serum albumin and liver cytosol on CYP2C9-and CYP3A4-mediated drug metabolism. Drug Metabolism and Pharmacokinetics 17 (2002) 522-531. https://doi.org/10.2133/dmpk.17.522 DOI: https://doi.org/10.2133/dmpk.17.522
[6] M. Trunzer, J. Teigão, F. Huth, B. Poller, S. Desrayaud, R. Rodríguez-Pérez, B. Faller. Improving in vitro-in vivo extrapolation of clearance using rat liver microsomes for highly plasma protein-bound molecules. Drug Metabolism and Disposition 52 (2024) 345-354. https://doi.org/10.1124/dmd.123.001597 DOI: https://doi.org/10.1124/dmd.123.001597
[7] S.P.F. Tan, A. Tillmann, S.J. Murby, A. Rostami-Hodjegan, D. Scotcher, A. Galetin. Albumin-Mediated Drug Uptake by Organic Anion Transporter 1/3 Is Real: Implications for the Prediction of Active Renal Secretion Clearance. Molecular Pharmaceutics 21 (2024) 4603-4617. https://doi.org/10.1021/acs.molpharmaceut.4c00504 DOI: https://doi.org/10.1021/acs.molpharmaceut.4c00504
[8] Y. Bi, S. Ryu, D.A. Tess, A.D. Rodrigues, M.V. Varma. Effect of human plasma on hepatic uptake of organic anion-transporting polypeptide 1B substrates: studies using transfected cells and primary human hepatocytes. Drug Metabolism and Disposition 49 (2021) 72-83. https://doi.org/10.1124/dmd.120.000134 DOI: https://doi.org/10.1124/dmd.120.000134
[9] Z. Yan, L. Ma, N. Hwang, J. Huang, J.R. Kenny, C.E. Hop. Using the dynamic well-stirred model to extrapolate hepatic clearance of organic anion-transporting polypeptide transporter substrates without assuming albumin-mediated hepatic drug uptake. Drug Metabolism and Disposition 52 (2024) 548-554. https://doi.org/10.1124/dmd.124.001645 DOI: https://doi.org/10.1124/dmd.124.001645
[10] Z. Yan, L. Ma, P. Carione, J. Huang, N. Hwang, J.R. Kenny, C.E. Hop. Introducing the dynamic well-stirred model for predicting hepatic clearance and extraction ratio. Journal of Pharmaceutical Sciences 113 (2024) 1094-1112. https://doi.org/10.1016/j.xphs.2023.12.020 DOI: https://doi.org/10.1016/j.xphs.2023.12.020
[11] Y. Fukuchi, K. Toshimoto, T. Mori, K. Kakimoto, Y. Tobe, T. Sawada, R. Asaumi, T. Iwata, Y. Hashimoto, K. Nunoya. Analysis of nonlinear pharmacokinetics of a highly albumin-bound compound: contribution of albumin-mediated hepatic uptake mechanism. Journal of Pharmaceutical Sciences 106 (2017) 2704-2714. https://doi.org/10.1016/j.xphs.2017.04.052 DOI: https://doi.org/10.1016/j.xphs.2017.04.052
[12] N. Li, A. Badrinarayanan, K. Ishida, X. Li, J. Roberts, S. Wang, M. Hayashi, A. Gupta. Albumin-Mediated Uptake Improves Human Clearance Prediction for Hepatic Uptake Transporter Substrates Aiding a Mechanistic In Vitro-In Vivo Extrapolation (IVIVE) Strategy in Discovery Research. The AAPS Journal 23 (2021) 1. https://doi.org/10.1208/s12248-020-00528-y DOI: https://doi.org/10.1208/s12248-020-00528-y
[13] C. Tang, Y. Lin, A.D. Rodrigues, J.H. Lin. Effect of albumin on phenytoin and tolbutamide metabolism in human liver microsomes: an impact more than protein binding. Drug Metabolism and Disposition 30 (2002) 648-654. https://doi.org/10.1124/dmd.30.6.648 DOI: https://doi.org/10.1124/dmd.30.6.648
[14] R. Weisiger, J. Gollan, R. Ockner. Receptor for Albumin on the Liver Cell Surface May Mediate Uptake of Fatty Acids and Other Albumin-Bound Substances. Science 211 (1981) 1048-1051. https://doi.org/10.1126/science.6258226 DOI: https://doi.org/10.1126/science.6258226
[15] R.K. Ockner, R.A. Weisiger, J.L. Gollan. Hepatic uptake of albumin-bound substances: albumin receptor concept. American Journal of Physiology-Gastrointestinal and Liver Physiology 245 (1983) G13-G18. https://doi.org/10.1152/ajpgi.1983.245.1.G13 DOI: https://doi.org/10.1152/ajpgi.1983.245.1.G13
[16] S. Miyauchi, M. Masuda, S.-J. Kim, Y. Tanaka, K.-R. Lee, S. Iwakado, M. Nemoto, S. Sasaki, K. Shimono, Y. Tanaka. The phenomenon of albumin-mediated hepatic uptake of organic anion transport polypeptide substrates: prediction of the in vivo uptake clearance from the in vitro uptake by isolated hepatocytes using a facilitated-dissociation model. Drug Metabolism and Disposition 46 (2018) 259-267. https://doi.org/10.1124/dmd.117.077115 DOI: https://doi.org/10.1124/dmd.117.077115
[17] M.S.C. Abreu, L.M.B.B. Estronca, M.J. Moreno, W.L.C. Vaz. Binding of a fluorescent lipid amphiphile to albumin and its transfer to lipid bilayer membranes. Biophysical Journal 84 (2003) 386-399. https://doi.org/10.1016/S0006-3495(03)74859-0 DOI: https://doi.org/10.1016/S0006-3495(03)74859-0
[18] K. Sugano, M. Kansy, P. Artursson, A. Avdeef, S. Bendels, L. Di, G.F. Ecker, B. Faller, H. Fischer, G. Gerebtzoff, H. Lennernaes, F. Senner. Coexistence of passive and carrier-mediated processes in drug transport. Nature Reviews Drug Discovery 9 (2010). https://doi.org/10.1038/nrd3187 DOI: https://doi.org/10.1038/nrd3187
[19] M. Kansy, F. Senner, K. Gubernator. Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. Journal of Medicinal Chemistry 41 (1998) 1007-1010. https://doi.org/10.1021/jm970530e DOI: https://doi.org/10.1021/jm970530e
[20] A. Avdeef, S. Bendels, L. Di, B. Faller, M. Kansy, K. Sugano, Y. Yamauchi. PAMPA - critical factors for better predictions of absorption. Journal of Pharmaceutical Sciences 96 (2007) 2893-2909. https://doi.org/10.1002/jps.21068 DOI: https://doi.org/10.1002/jps.21068
[21] B. Faller, H.P. Grimm, F. Loeuillet-Ritzler, S. Arnold, X. Briand. High-throughput lipophilicity measurement with immobilized artificial membranes. Journal of Medicinal Chemistry 48 (2005) 2571-2576. https://doi.org/10.1021/jm049377w DOI: https://doi.org/10.1021/jm049377w
[22] A. Bujard, M. Sol, P.-A. Carrupt, S. Martel. Predicting both passive intestinal absorption and the dissociation constant toward albumin using the PAMPA technique. European Journal of Pharmaceutical Sciences 63 (2014) 36-44. https://doi.org/10.1016/j.ejps.2014.06.025 DOI: https://doi.org/10.1016/j.ejps.2014.06.025
[23] A. Bujard, C. Petit, P.-A. Carrupt, S. Rudaz, J. Schappler. HDM-PAMPA to predict gastrointestinal absorption, binding percentage, equilibrium and kinetics constants with human serum albumin and using 2 end-point measurements. European Journal of Pharmaceutical Sciences 97 (2017) 143-150. https://doi.org/10.1016/j.ejps.2016.11.001 DOI: https://doi.org/10.1016/j.ejps.2016.11.001
[24] S. Yamauchi, K. Sugano. Permeation characteristics of tetracyclines in parallel artificial membrane permeation assay. ADMET and DMPK 7 (2019) 151-160. https://doi.org/10.5599/admet.657 DOI: https://doi.org/10.5599/admet.657
[25] Viatris Pharmaceuticals Japan Inc. Atorvastatin Drug Product Information. https://www.viatris-e-channel.com/viatris-products/di/detail/assetfile/Lipitor_Tab_IF.pdf (accessed March 22, 2016) in Japanese
[26] Y. Higashiguchi, S. Ishida, S. Lee, B. Sinko, K. Box, K. Sugano. Predicting Food Effect On Oral Drug Absorption For Solubility-Epithelial Membrane Permeation-Limited Cases With Bile Micelle Solubilization. Pharmaceutical Research 42 (2025) 1837-1855. https://doi.org/10.1007/s11095-025-03947-8 DOI: https://doi.org/10.1007/s11095-025-03947-8
[27] Actelion Pharmaceuticals Ltd, Actelion Ltd. Bosentan Drug Product Information. https://pins.japic.or.jp/pdf/medical_interview/IF00003694.pdf (accessed July 22, 2025) in Japanese
[28] A. Avdeef. Absorption and Drug Development: Solubility, Permeability, and Charge State, John Wiley & Sons, 2012. https://doi.org/10.1002/047145026X DOI: https://doi.org/10.1002/9781118286067
[29] Kowa Company, Ltd. Pitavastatin Drug Product Information. https://medical.kowa.co.jp/asset/item/50/1-pi_124.pdf (accessed December 5, 2010) in Japanese
[30] J. Savolainen, M. Forsberg, H. Taipale, P.T. Männistö, K. Järvinen, J. Gynther, P. Jarho, T. Järvinen. Effects of aqueous solubility and dissolution characteristics on oral bioavailability of entacapone. Drug Development Research 49 (2000) 238-244. https://doi.org/10.1002/1098-2299(200004)49:4%3C238::AID-DDR2%3E3.0.CO;2-V DOI: https://doi.org/10.1002/1098-2299(200004)49:4<238::AID-DDR2>3.0.CO;2-V
[31] Novartis Pharma Co., Ltd. Entacapone Drug Product Information. https://www.gifu-upharm.jp/di/mdoc/iform/2g/i1307022310.pdf (accessed September 2, 2021)
[32] P. Luger, K. Daneck, W. Engel, G. Trummlitz, K. Wagner. Structure and physicochemical properties of meloxicam, a new NSAID. European Journal of Pharmaceutical Sciences 4 (1996) 175-187. https://doi.org/10.1016/0928-0987(95)00046-1 DOI: https://doi.org/10.1016/0928-0987(95)00046-1
[33] AstraZeneca, Rosuvastatin Drug Product Information. https://med.astrazeneca.co.jp/product/CRS.html (accessed September 7, 2026)
[34] O. Tsinman, K. Tsinman, N. Sun, A. Avdeef. Physicochemical Selectivity of the BBB Microenvironment Governing Passive Diffusion- Matching with a Porcine Brain Lipid Extract Artificial Membrane Permeability Model. Pharmaceutical Research 28 (2011) 337-363. https://doi.org/10.1007/s11095-010-0280-x DOI: https://doi.org/10.1007/s11095-010-0280-x
[35] A. Avdeef, P.E. Nielsen, O. Tsinman. PAMPA - A drug absorption in vitro model: 11. Matching the in vivo unstirred water layer thickness by individual-well stirring in microtitre plates. European Journal of Pharmaceutical Sciences 22 (2004) 365-374. https://doi.org/10.1016/j.ejps.2004.04.009 DOI: https://doi.org/10.1016/S0928-0987(04)00121-6
[36] E. Barta, S. Sideman, J.B. Bassingthwaighte. Facilitated Diffusion and Membrane Permeation of Fatty Acid in Albumin Solutions. Annals of Biomedical Engineering 28 (2000) 331-345. https://doi.org/10.1114/1.274 DOI: https://doi.org/10.1114/1.274
[37] K. Sugano, Y. Nabuchi, M. Machida, Y. Asoh. Permeation characteristics of a hydrophilic basic compound across a bio-mimetic artificial membrane. International Journal of Pharmaceutics 275 (2004). https://doi.org/10.1016/j.ijpharm.2004.02.010 DOI: https://doi.org/10.1016/j.ijpharm.2004.02.010
[38] Z.S. Teksin, K. Hom, A. Balakrishnan, J.E. Polli. Ion pair-mediated transport of metoprolol across a three lipid-component PAMPA system. Journal of Controlled Release 116 (2006) 50-57. https://doi.org/10.1016/j.jconrel.2006.08.020 DOI: https://doi.org/10.1016/j.jconrel.2006.08.020
[39] A. Avdeef. Anomalous solubility behavior of several acidic drugs. ADMET and DMPK 2 (2014) 33-42. https://doi.org/10.5599/admet.2.1.30 DOI: https://doi.org/10.5599/admet.2.1.30
[40] Y. Kanda. Investigation of the freely available easy-to-use software ‘EZR’for medical statistics. Bone Marrow Transplantation 48 (2013) 452-458. https://doi.org/10.1038/bmt.2012.244 DOI: https://doi.org/10.1038/bmt.2012.244
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Mayu Konishi, Kiyohiko Sugano
This work is licensed under a Creative Commons Attribution 4.0 International License.
